Results 41 to 50 of about 1,268 (176)

Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy [PDF]

, 2023
International audienceAbstract Objective Immune-mediated necrotizing myopathies (IMNMs) are severe forms of myositis often associated with pathogenic anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies (aAbs).
van der Woning, Bas, de Ceuninck, Leentje, Drouot, Laurent, Sarah Julien, Olivier Benveniste, Thara Jaworski, Olivier Boyer, Yves Allenbach, Gaëlle Roussel, Rachid Zoubaïri, Briand, Emma, Jaworski, Thara, Leentje De Ceuninck, Laurent Drouot, Roussel, Gaëlle, Boyer, Olivier, Zoubaïri, Rachid, Allenbach, Yves, Benveniste, Olivier, Bas van der Woning, Emma Briand, Julien, Sarah   +21 more
core   +1 more source

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis [PDF]

, 2019
Objective: To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR ...
Damme, P. van, Tuan Vu, Burns, Ted M., Bilinska, Malgorzata, Said Beydoun, Ulrichts, P., Frangiomore, R., De Rivera Garrido, Francisco Javier Rodriguez, Burns, Ted M, Freimer, Miriam, Chopra, Manisha, Burns, T.M., Chopra, M., Andrzej Szczudlik, Fredrik Piehl, Tuan, Vu, Efgartigimod MG Study Grp, Guglietta, A., Amelia Evoli, Szczudlik, Andrzej, Ulrichts, Peter, Mantegazza, R., Szczudlik, A., Haard, H. de, Garrido, F.J.R.D., Farias, J., Verschuuren, Jan J.G.M., Miriam Freimer, Howard, J.F., Diez-Tejedor, E., Heintzman, S., Diez-Tejedor, Exuperio, Beydoun, S., Howard, James F, Meel, R. de, Heintzman, Sarah, Claeys, K., Sgarzi, Manlio, Howard, James F., Mathew, Veena, Van Damme, Phillip, Vu, T., Freimer, M., Leupin, N., Piehl, Fredrik, Mozaffar, T., Renato Mantegazza, Mathew, V., Farias, Jerrica, Philip Van Damme, Vu, Tuan, de Meel, Robert, Frangiomore, Rita, Mantegazza, Renato, Ward, E.S., Evoli, Amelia, Rottoli, Mariarosa, Ward, E. Sally, Evoli, A., Dreier, Torsten, Efgartigimod MG Study Group, Francisco Javier Rodriguez De River Garrido, Ward, E Sally, Katrien Verschueren, Piehl, F., Garrido, Francisco Javier Rodriguez De Rivera, Bilinska, M., Evoli A, Verschuuren, J.J.G.M., Jan J.G.M. Verschuuren, Genge, A., Harvey, B.L., Antonio Guglietta, Verschuuren, Jan J.GM., Sgarzi, M., Leupin, Nicolas, Mariarosa Rottoli, Guglietta, Antonio, Dreier, T., Alboini, P.E., Genge, Angela, de Haard, Hans, Ted M. Burns, Van Damme, Philip, Harvey, Brittany Leigh, Torsten Dreier, Verschuuren, Jan JGM, Rodriguez De Rivera Garrido, Francisco Javier, Bril, V., Peter Ulrichts, Mozaffar, Tahseen, Claeys, Kristl, E. Sally Ward, Nicolas Leupin, Bril, Vera, Verschueren, Katrien, Tahseen Mozaffar, Hietala, A., Verschueren, K., Malgorzata Bilinska, Vera Bril, Piehl, Fredrick, Hans de Haard, Alboini, Paolo Emilio, James F. Howard, Rottoli, M., Beydoun, Said, Hietala, Albert   +107 more
core   +1 more source

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia [PDF]

, 2020
Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, characterized by a low platelet count (<100 × 10 9/L) in the absence of other causes associated with thrombocytopenia.
de Haard, Hans, David J. Kuter, Miklos Egyed, Torsten Dreier, Gandini, Domenica, Newland, Adrian C., Michel, Marc, Sánchez‐González, Blanca, Kuter, David J., László Rejtő, Ward, E. Sally, Domenica Gandini, Dreier, Torsten, Jon Beauchamp, Sánchez González, Blanca, Godar, Marie, Nataliya Romanyuk, Howard A. Liebman, Liebman, Howard A., Peter Ulrichts, Katrien Verschueren, E. Sally Ward, Nicolas Leupin, Verschueren, Katrien, Romanyuk, Nataliya, Blanca Sánchez‐González, Rejtő, László, Adrian C. Newland, Marc Michel, Haard, Hans, Beauchamp, Jon, Ulrichts, Peter, Leupin, Nicolas, Marie Godar, Hans de Haard, Egyed, Miklos   +35 more
core   +1 more source

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans [PDF]

, 2018
BACKGROUND: Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune diseases mediated by pathogenic IgG autoantibodies.
Hofman, Erik, Vankerckhoven, Bernhardt, de Haard, Hans, Torsten Dreier, JunHaeng Cho, Raimund J. Ober, Ward, E. Sally, Dreier, Torsten, van Bragt, Tonke, Bernhardt Vankerckhoven, Erik Hofman, Tonke van Bragt, Lykhopiy, Valentina, Cho, JunHaeng, F. Javier Enriquez, Ober, Raimund J, Peter Ulrichts, E. Sally Ward, Nicolas Leupin, Ongenae, Nicolas, Verheesen, Peter, Enriquez, F Javier, Hanssens, Valérie, Antonio Guglietta, Valentina Lykhopiy, Ulrichts, Peter, Leupin, Nicolas, Guglietta, Antonio, Valérie Hanssens, Hans de Haard, Peter Verheesen, Nicolas Ongenae   +31 more
core   +1 more source

A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients [PDF]

Introduction: Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients.
Garibaldi, Matteo, Sacca, Francesco, Marsili, Angela, Puorro, Giorgia, Di Stefano, Vincenzo, Brighina, Filippo, Rini, Nicasio, Sarnataro, Alessio, Cuomo, Nunzia, Vinciguerra, Claudia, Bevilacqua, Liliana, Pane, Chiara, Fionda, Laura   +12 more
core   +4 more sources

Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis

Autoimmunity, 2022
Antagonism of the neonatal Fc receptor (FcRn) by efgartigimod has been studied in several autoimmune diseases mediated by immunoglobulin G (IgG) as a therapeutic approach to remove pathogenic IgGs.
Jeffrey T. Guptill, John W. Sleasman, Sophie Steeland, Magdalena Sips, Deborah Gelinas, Hans de Haard, Antoine Azar, Kevin L. Winthrop   +7 more
doaj   +1 more source

Efgartigimod: a breakthrough medicine for myasthenia gravis

International Journal of Surgery: Global Health, 2022
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction origin that causes persistent fatigue and weakening of voluntary muscles. MG is the most prevalent neuromuscular junction disorder, with an estimated 150–200 new cases per million individuals per year.
Omer Ahmed Shaikh, Rahma Idrees, Rameel Muhammad Aftab, Gulrukh Shaikh, Sidhant Ochani, Kaleem Ullah   +5 more
openaire   +1 more source

Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study

BMJ Neurology Open
Introduction Myasthenia gravis (MG), an IgG-mediated autoimmune disorder targeting neuromuscular junctions, shows refractory in 12–20% of generalised MG (gMG) patients despite immunotherapies.
Lu Zhang, Kan Wang, Yong Hao, Yangtai Guan, Jing Peng, Li Gao, Song Gao, Qiuju Li, Chong Xie, Yuhui Wang, Yanan Wu, Mengze Zhang, Xiaokun Wang, Chunran Xue, Yiwei Yang   +14 more
doaj   +1 more source

Fatigue in Myasthenia Gravis: Recent Advances and Emerging Concepts

Muscle &Nerve, EarlyView.
ABSTRACT Fatigue is a common, often disabling symptom in myasthenia gravis (MG), distinct from muscle fatigability, and strongly associated with reduced quality of life. This narrative review examines current evidence on fatigue in MG, its patient impact, and future research directions. Earlier studies, mostly small and heterogeneous, reported a highly
Yvonne J. M. Campman, Martijn R. Tannemaat, Annabel M. Ruiter, Sarah Hoffmann   +3 more
wiley   +1 more source

Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial [PDF]

, 2022
Background Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins.
de Haard H., Csörgő Sándorné Bata Zsuzsanna, Stoevesandt J., Dupuy P., De Simone C., Joly P., Kollaborációs szervezet: ARGX-113-1701 Investigator Study Group, Schmidt E., Verheesen P., Goebeler M., Didona B., Remenyik Éva, Reznichenko N., Ward E. S., Parys W.   +14 more
core   +3 more sources